XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Equity Incentive Plans
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

NOTE 10.  Equity Incentive Plans

 

On April 23, 2019, the Company’s stockholders approved the adoption of the 2019 Equity Incentive Plan (the “2019 Plan”), under which the Company is authorized to issue incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards and restricted stock units, other stock awards and performance awards that may be settled in cash, stock, or other property. The 2019 Plan is designed to secure and retain the services of employees, directors and consultants, provide incentives for the Company’s employees, directors and consultants to exert maximum efforts for the success of the Company and its affiliates, and provide a means by which employees, directors and consultants may be given an opportunity to benefit from increases in the value of the Company’s common stock. Following adoption of the 2019 Plan, all previous plans were frozen, and on forfeiture, cancellation and expiration, awards under those plans are not assumed by the 2019 Plan.

 

The aggregate number of shares of common stock authorized for issuance under the 2019 Plan was initially 1,600,000 shares, which was increased through an amendment to the 2019 Plan adopted by the Company’s stockholders (a “Plan Amendment”) on June 8, 2020, to 8,000,000, and by a Plan Amendment on June 16, 2021, to 16,900,000. Further amendments to the 2019 Plan to increase the share reserve would require stockholder approval. Awards that are forfeited or canceled generally become available for issuance again under the 2019 Plan. Awards have a maximum term of ten years from the grant date and may vest over varying periods, as specified by the Company’s board of directors for each grant.

 

A summary of stock option transactions in the nine months ended September 30, 2021, is as follows:

          

Weighted

 
  

Shares

  

Number of

  

Average

 
  

Available

  

Options

  

Exercise

 
  

For Grant

  

Outstanding

  

Price

 
             

Balance at January 1, 2021

  1,230,863   6,813,033  $2.70 

2019 Plan Amendment

  8,900,000     $ 

Granted

  (4,122,438)  4,122,438  $7.24 

Exercised

     (771,344) $1.61 

Forfeited

  554,317   (574,054) $2.44 

Canceled

     (36,315) $8.42 
             

Balance at September 30, 2021

  6,562,742   9,553,758  $4.74 

 

As of September 30, 2021, there were 9,553,758 options outstanding with a weighted average exercise price of $4.74, a weighted average remaining term of 8.55 years and an aggregate intrinsic value of $32.1 million. Of these options, 3,665,542 were vested, with a weighted average exercise price of $2.67, a weighted average remaining term of 7.27 years and an aggregate intrinsic value of $20.1 million. The Company received $1.2 million for the 771,344 options exercised during the nine months ended September 30, 2021, which had an intrinsic value of $4.6 million, and received $402,000 for the 305,179 options exercised during the nine months ended September 30, 2020, which had an intrinsic value of $1.6 million.

 

The weighted average grant date fair value of options awarded in the nine months ended September 30, 2021 and 2020, was $6.67 and $1.98, respectively. Their fair values were estimated using the following assumptions:

 

  

Nine Months Ended September 30,

 
  

2021

  

2020

 
         

Risk-free interest rate

  0.91% - 1.19%   0.40% - 0.88% 

Expected term (in years)

  5.44 - 6.08   5.22 - 10.00 

Expected volatility

  122% - 131%   94% - 108% 

Dividend yield

  %  %

 

The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options was as follows:

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2021

  

2020

  

2021

  

2020

 
                 

Research and development

 $1,206  $268  $2,429  $1,405 

General and administrative

  893   647   3,525   2,466 

Total stock-based compensation

 $2,099  $915  $5,954  $3,871 

 

Effective June 16, 2021, the Company modified the terms of outstanding options awarded to its former Chairman of the Board, Wouter W. Latour, such that the vesting of 100,000 options that would otherwise have been forfeited was accelerated. Further, the post-termination exercise period for all his vested and outstanding options as of the termination date was extended from three months to the earlier of the expiry of their ten-year term and June 16, 2023. The Company recorded a charge for the incremental increase in fair value of $1.3 million, which was included in stock-based compensation expense within general and administrative expenses in the three months ended June 30, 2021.

 

As of September 30, 2021, the unrecognized stock-based compensation cost related to outstanding unvested stock options was $25.8 million, which the Company expects to recognize over an estimated weighted average period of 3.08 years.